A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with ...
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagu...
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous th...
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also call...
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamet...
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamet...
Top Cities for Deep Vein Thrombosis Clinical Trials
Deep Vein Thrombosis clinical trials are recruiting across 41 cities. Here are the cities with the most active studies:
About Deep Vein Thrombosis
Deep vein thrombosis (DVT) occurs when a blood clot forms in a deep vein, usually in the legs. It can be dangerous if the clot breaks loose and travels to the lungs (pulmonary embolism). Treatment includes blood thinners and sometimes clot-removal procedures.
Clinical trials are advancing new treatments for deep vein thrombosis. Currently, 6 studies are recruiting a combined 1,941 participants across the United States. Research is being conducted by 5 organizations including Anthos Therapeutics, Inc., Takeda, Yale University and 2 others.
2026 Deep Vein Thrombosis Research Landscape
As of March 2026, the deep vein thrombosis clinical trial landscape includes 6 actively recruiting studies across 41 cities in the United States. These studies are collectively seeking 1,941 participants, with an average enrollment target of 324 per study.
Research is being led by 5 different organizations, including Anthos Therapeutics, Inc., Takeda, Yale University, Regeneron Pharmaceuticals, Mercator MedSystems, Inc..
Geographically, deep vein thrombosis trials are most concentrated in Miami, Florida (4 trials); Boston, Massachusetts (3 trials); New York, New York (3 trials); Aurora, Colorado (2 trials); Washington D.C., District of Columbia (2 trials) and 7 other cities.
Featured Deep Vein Thrombosis Studies
Highlighted recruiting studies for deep vein thrombosis, selected by enrollment size and research scope.
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagulation reversal in participants treated with Factor Xa inhibitors who require urgent surgery/invasive procedure. The participant will be assigned by chance to either TAK-330 or SOC 4F-PCC as part of ...
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous thrombosis in critically ill children.
Frequently Asked Questions About Deep Vein Thrombosis Clinical Trials
Are there deep vein thrombosis clinical trials near me?
Yes, there are 6 deep vein thrombosis clinical trials currently recruiting across 41+ cities in the United States, including Miami, Florida; Boston, Massachusetts; New York, New York. Browse the studies above to find one at a location convenient for you.
How do I join a deep vein thrombosis clinical trial?
To join a deep vein thrombosis clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are deep vein thrombosis clinical trials free?
Yes, participation in deep vein thrombosis clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of deep vein thrombosis treatments are being studied?
Current deep vein thrombosis clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 5 research organizations.
Is it safe to participate in deep vein thrombosis clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov